Analysts Set Fractyl Health, Inc. (NASDAQ:GUTS) Target Price at $5.40

Fractyl Health, Inc. (NASDAQ:GUTS) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $5.40.

GUTS has been the topic of a number of analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fractyl Health in a research report on Monday, December 29th. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $8.00 to $2.00 in a research note on Thursday, January 29th.

Institutional Investors Weigh In On Fractyl Health

Several hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new position in shares of Fractyl Health in the 2nd quarter worth $31,000. FNY Investment Advisers LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $31,000. Scientech Research LLC bought a new stake in shares of Fractyl Health during the 3rd quarter worth $49,000. Prelude Capital Management LLC purchased a new position in Fractyl Health in the third quarter worth $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Fractyl Health in the third quarter worth $56,000.

Fractyl Health Stock Down 1.9%

GUTS stock opened at $0.46 on Friday. The stock has a 50-day simple moving average of $0.59 and a two-hundred day simple moving average of $1.26. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $3.03. The firm has a market capitalization of $72.33 million, a PE ratio of -0.25 and a beta of 1.20. The company has a quick ratio of 4.78, a current ratio of 4.78 and a debt-to-equity ratio of 3.23.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.34. On average, equities analysts predict that Fractyl Health will post -1.61 EPS for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.